Hôpital Foch

The research team at Hôpital Foch is evaluating new post‑surgical strategies for ampullary adenocarcinoma, aiming to increase the proportion of patients who remain cancer‑free two years after operation.

• Adjuvant chemotherapy after surgical resection
• Modified FOLFIRINOX regimen versus standard agents
• Improving two‑year disease‑free survival rates

This work reflects the site’s commitment to advancing treatment options for rare gastrointestinal tumors.

A pivotal study at Hôpital Foch investigates a novel combination of LY3537982 with pembrolizumab for patients whose KRAS G12C‑mutant non‑small cell lung cancer is advanced, seeking to define the most effective first‑line regimen.

• First‑line targeted therapy for KRAS‑mutated lung cancer
• Combination with immunotherapy to boost response
• Dose‑optimization to balance efficacy and safety

The trial highlights the centre’s focus on precision oncology and collaborative drug development.

Two parallel programs at Hôpital Foch address critical lung and vascular conditions: one examines intravenous thrombolysis in patients with acute ischemic stroke who have recently taken direct oral anticoagulants, while the other compares antifungal strategies—including itraconazole plus nebulised Ambisome®—for chronic pulmonary aspergillosis.

• Evaluating IV thrombolysis safety in anticoagulated stroke patients
• Optimizing antifungal regimens for chronic lung infection
• Measuring clinical and radiological outcomes across both studies

These investigations illustrate the department’s dedication to improving outcomes in both vascular emergencies and persistent respiratory infections.

Beyond disease‑specific projects, Hôpital Foch conducts a suite of clinical trials that integrate multidisciplinary expertise, rigorous safety oversight, and patient‑focused design across four therapeutic domains.

• Multidisciplinary collaboration among four investigators
• Patient‑centered trial design and enrollment
• Comprehensive safety monitoring across studies

The site’s diverse portfolio underscores its role as a leading hub for innovative clinical research in Europe.